Shares of Lexeo Therapeutics Inc. (LXEO) are up over 20% at $2.81 in premarket trading Monday, following positive interim data for LX2006 in Friedreich ataxia cardiomyopathy from the SUNRISE-FA trial and the Weill Cornell Medicine investigator-initiated study.
LX2006 is an AAV-based gene therapy candidate for the treatment of Friedreich ataxia (FA) cardiomyopathy, the leading cause of death in individuals with FA affecting approximately 5,000 people in the United States. Friedreich ataxia, a rare inherited condition that affects the nervous system, is caused by a mutation in FXN, a gene that provides instructions for making the mitochondrial protein frataxin.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com